1258428-71-5

Basic information

• Product Name: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone
• Synonyms: Montelukast Related Impuirty 1;1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone;(E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-one;Montelukast Sodium Impurity A
• CAS NO: 1258428-71-5
• Molecular Formula: C29H26ClNO2
• Molecular Weight: 455.97524
• EINECS: -0
• Product Categories: Chiral Reagents, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 1258428-71-5.mol

Chemical Properties

• Boiling Point: 651.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: Amber Vial, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 14.46±0.29(Predicted)
• CAS DataBase Reference: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(1258428-71-5)
• EPA Substance Registry System: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(1258428-71-5)

Safety Data

• Hazardous Substances Data: 1258428-71-5(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone is used as an impurity in Montelukast (M568000) for [application type] as an antiasthmatic. [application reason] It is a selective leukotriene D4-receptor antagonist that helps in managing asthma symptoms by blocking the action of leukotrienes, which are inflammatory mediators.

Upstream product

• 7073-69-0 2-(2-bromophenyl)propanol 
• 149968-10-5 (E)-3-<2-(7-chloro-2-quinolinyl)ethenyl>-α-ethenylphenylmethanol 
• 88-65-3 2-bromobenzoic-acid 
• 88-67-5 2-Iodobenzoic acid 
• 69352-05-2 2-(2-iodophenyl)propan-2-ol 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 1208128-87-3 2-(2-ortho(2-bromoethyl)phenylpropyl)tetrahydropyran ether 
• 1208128-84-0 3-(2-(7-chloro-2-quinolyl)vinyl)benzonitrile 
• 1208128-85-1 2-(2-orthomethylphenylpropyl)tetrahydropyrane ether 
• 7572-79-4 2-(2-methylphenyl)propan-2-ol 
• 577-16-2 2-Methylacetophenone 
• 4965-33-7 2-methyl-7-chloroquinoline 
• 24964-64-5 3-Cyanobenzaldehyde 
• 177748-00-4 7-chloro-2-ethenylquinoline 

Downstream Products

• 1359172-54-5 (S)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxy-ethyl)-phenyl]-propan-1-ol 
• 1359172-33-0 C₃₃H₃₈ClNO₄SSi 
• 1359172-36-3 (1-{(R)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)vinyl]phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxyethyl)phenyl]propylsulfanylmethyl}cyclopropyl)acetic acid methyl ester 

Relevant articles and documents

An enantioselective formal synthesis of montelukast sodium

A formal synthesis of the antiasthma drug montelukast sodium is described, wherein the key chiral diol intermediate was accessed with greater convergence of the C-C bond-forming steps as compared to previous routes. Improved synthetic efficiency was achie

For the synthesis of montelukast intermediate compound and its preparation method

The invention relates to a pharmaceutical intermediate and a preparation method thereof, and especially relates to an intermediate compound represented by the formula (1) for synthesizing montelukast; wherein in the formula the X' represents a halogen ele

PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS

The present invention relates to an improved process for the preparation of a compound having formula (I). The compound having formula (I) is the backbone diol precursor/intermediate used to produce montelukast sodium. Montelukast sodium is a leukotriene

SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE

A synthesis method for preparing Montelukast sodium intermediate 2-(2-(3-(2-(7-chloro-2-quinolyl)vinyl)phenyl-3-oxopropyl)phenyl) propanol is provided. In this method, the target compound is prepared by condensing the starting materials 7-chloroquinaldine and 3-cyanobenzaldehyde, and then reacting the resultant product with 2-(2-ortho-(2-haloethyl)-phenylpropyl)tetrahydropyrane ether. The present invention can easily obtain start materials and is applicable for mass production.

PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM

The present invention relates to a process for the synthesis of Montelukast sodium of formula I the chemical name of which is [(R)-(E)]-1-[[[1-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl] -3 - [2-( 1 -hydroxy- 1 -methylethyl)phenyl]propyl] thio]methyl] - -cyclopropaneacetic acid sodium salt. The present invention further provides compounds of general formulae V, VI, VIb and VIII as new intermediates.

PREPARATION OF MONTELUKAST

Processes for the preparation of montelukast and its salts.